Ellipticine hydrochloride 玫瑰树碱盐酸盐; NSC 71795 hydrochloride|cas:5081-48-1|西域试剂

Ellipticine hydrochloride 玫瑰树碱盐酸盐; NSC 71795 hydrochloride,99.45%

产品编号：Bellancom-15753A| CAS NO：5081-48-1| 分子式：C₁₇H₁₅ClN₂| 分子量：282.77

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-15753A	￥550.00	杭州北京（现货）
Bellancom-15753A	￥880.00	杭州北京（现货）
Bellancom-15753A	￥3500.00	杭州北京（现货）
Bellancom-15753A	￥6200.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Ellipticine hydrochloride 玫瑰树碱盐酸盐; NSC 71795 hydrochloride

产品介绍

Ellipticine (NSC 71795) hydrochloride是一种有效的抗肿瘤剂; 抑制DNA拓扑异构酶II活性。

生物活性

Ellipticine (NSC 71795) hydrochloride is a potent antineoplastic agent; inhibits DNA topoisomerase II activities.

体外研究

Ellipticine (NSC 71795) is a potent antineoplastic agent exhibiting the multimodal mechanism of its action. The mechanisms of Ellipticine (NSC 71795) antitumor, mutagenic and cytotoxic activities are suggested to be intercalation into DNA and inhibition of DNA topoisomerase II activity. Another mode of Ellipticine (NSC 71795) action is the formation of covalent DNA adducts mediated by its oxidation with cytochromes P450 (CYP) and peroxidases. Ellipticine (NSC 71795) can also act as an inhibitor or inducer of biotransformation enzymes, thereby modulating its own metabolism leading to its genotoxic and pharmacological effects. Treatment of cells with Ellipticine (NSC 71795) results in inhibition of cell growth and proliferation. This effect is associated with formation of two covalent Ellipticine (NSC 71795)-derived DNA adducts.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Ellipticine (NSC 71795) treatment results in ellipticine-derived DNA adduct generation in several healthy organs (liver, kidney, lung, spleen, breast, heart and brain) and in DNA of mammary adenocarcinoma. The levels of Ellipticine (NSC 71795)-derived DNA adducts generated in these adenocarcinomas are almost 2-fold higher than in normal healthy mammary tissue. The induced expression of cytochrome b₅ protein in liver of rats treated with Ellipticine (NSC 71795) suggests that cytochrome b₅ may modulate the CYP-mediated bioactivation and detoxification of Ellipticine (NSC 71795).

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

性状

Solid

溶解性数据

In Vitro:

DMSO : 5.8 mg/mL (20.51 mM; Need ultrasonic and warming)

H₂O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.5364 mL	17.6822 mL	35.3644 mL
5 mM	0.7073 mL	3.5364 mL	7.0729 mL
10 mM	0.3536 mL	1.7682 mL	3.5364 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 0.84 mg/mL (2.97 mM); Clear solution

此方案可获得 ≥ 0.84 mg/mL (2.97 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 8.4 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 0.84 mg/mL (2.97 mM); Clear solution

此方案可获得 ≥ 0.84 mg/mL (2.97 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 8.4 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 0.84 mg/mL (2.97 mM); Clear solution

此方案可获得 ≥ 0.84 mg/mL (2.97 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 8.4 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。